<DOC>
	<DOCNO>NCT01983735</DOCNO>
	<brief_summary>The aim present study evaluate efficacy safety two dose combination Telmisartan/S-Amlodipine ( 80/2.5mg 80/5mg ) compare S-Amlodipine monotherapy ( 2.5mg 5mg ) patient Stage 2 hypertension .</brief_summary>
	<brief_title>Efficacy Safety TELMINUVO Stage 2 Hypertension</brief_title>
	<detailed_description>- In patient Stage 2 hypertension determine efficacy safety Telmisartan/S-Amlodipine ( 80/2.5mg 80/5mg ) S-Amlodipine monotherapy ( 2.5mg 5mg ) 8 week . - This study consist placebo run-in period ( 2 weeks_single blind ) treatment period ( 8 weeks_double blind ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>age 18 year old screen visit antihypertensive drug take : 160mmHg ≤ sitSBP &lt; 200mmHg antihypertensive drug take : 140mmHg ≤ sitSBP &lt; 180mmHg randomization visit ( 160mmHg ≤ sitSBP &lt; 200mmHg ) willing able provide write informed consent mean sit DBP ≥ 120mmHg mean sit SBP ≥ 200mmHg screen visit randomization visit past four week base begin administration , patient take four antihypertensive drug know suspect secondary hypertension ( ex . aortic coarctation , Primary hyperaldosteronism , renal artery stenosis , pheochromocytoma ) severe heart disease ( Heart failure NYHA functional class 3 , 4 ) , ischaemic heart diseases status need treatment , myocardiopathy , Valve disease , arrhythmia operate Coronary angioplasty cerebrovascular disease cerebral infarction , cerebral hemorrhage within 6 month Type I Diabetes Mellitus , Type II Diabetes Mellitus poor glucose control define fast glucosylated hemoglobin ( HbA1c ) &gt; 8 % ) know severe malignant retinopathy define follow laboratory parameter : hepatic dysfunction ( AST/ALT &gt; UNL X 3 ) renal dysfunction ( serum creatinine &gt; UNL X 1.5 ) hypopotassemia ( K &lt; 3.0mmol/L ) hyperpotassemia ( K &gt; 5.5 mmol/L ) acute chronic inflammatory status need treatment need additional antihypertensive drug study need concomitant medication know affect blood pressure study history angioedema related ACE inhibitor Angiotensin II Receptor Blockers know hypersensitivity relate either study drug history drug alcohol dependency within 6 month surgical medical condition might significantly alter absorption , distribution , metabolism , excretion investigational product ( ex . gastrointestinal tract surgery gastrectomy , gastroenterostomy bypass , active inflammatory bowel syndrome within 12 month prior screen , gastric ulcer need treatment , gastrointestinal/rectal bleeding , impaired pancreatic function pancreatitis , obstruction urinary tract difficulty void ) administration study drug within 4weeks prior screen premenopausal woman ( last menstruation &gt; 1year ) use adequate contraception , pregnant breastfeed history malignancy include leukemia lymphoma within past 5 year investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>TELMINUVO Tab .</keyword>
	<keyword>CKD-828</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Stage 2 Hypertension</keyword>
	<keyword>S-Amlodipine</keyword>
	<keyword>Telmisartan</keyword>
</DOC>